Oral zinc sulphate supplementation for six months in SCA2 patients: A randomized, double-blind, placebo-controlled trial

Neurochemical Research

Volumn 36, Issue 10, 2011, Pages 1793-1800

  Velázquez Pérez, Luis ^a   Rodríguez Chanfrau, Jorge ^b   García Rodríguez, Julio Cesar ^c   Sánchez Cruz, Gilberto ^a   Aguilera Rodríguez, Raúl ^a   Rodríguez Labrada, Roberto ^a   Rodríguez Díaz, Julio Cesar ^a   Canales Ochoa, Nalia ^a   Gotay, Dennis Almaguer ^a   Almaguer Mederos, Luis E ^a   Laffita Mesa, José M ^a   Porto Verdecia, Marlene ^b   Triana, Consuelo González ^a   Pupo, Noemí Rodríguez ^d   Batista, Idania Hidalgo ^e   López Hernandez, Orestes D ^b   Polanco, Iverlis Díaz ^b   Novas, Arelis Jayme ^f  

^a Centro para la Investigacion y Rehabilitacion de las Ataxias Hereditarias Cuba   (Cuba)

^b Centro de Desarrollo e Investigación de Medicamentos   (Cuba)

^c Centro Nacional Para La Producción De Animales De Laboratorio   (Cuba)

^d Hospital Provincial de Medicina Natural y Tradicional   (Cuba)

^e Hospital Clinico Quirurgico Lucia Iniguez Landin   (Cuba)

^f Instituto Nacional de Salud del Trabajo   (Cuba)

Author keywords

Clinical trial; SCA2; Spinocerebellar ataxia 2; Zn supplementation

Indexed keywords

ADVANCED OXIDATION PROTEIN PRODUCT; CATALASE; LIPID; MALONALDEHYDE; PLACEBO; SUPEROXIDE DISMUTASE; ZINC; ZINC SULFATE;

ADULT; ARTICLE; BODY POSTURE; CEREBROSPINAL FLUID LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CUBA; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSDIADOCHOKINESIA; GAIT; HUMAN; LIPID METABOLISM; LIPID PEROXIDATION; MOTOR DYSFUNCTION; NEUROREHABILITATION CARE; OUTCOME ASSESSMENT; OXIDATIVE STRESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REHABILITATION CARE; SACCADIC EYE MOVEMENT; SCORING SYSTEM; SPINOCEREBELLAR ATAXIA TYPE 2; SPINOCEREBELLAR DEGENERATION; STANDING; SUPPLEMENTATION; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; ZINC BLOOD LEVEL;

ADOLESCENT; ADULT; CATALASE; CUBA; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; HUMANS; MALONDIALDEHYDE; MIDDLE AGED; PLACEBOS; SACCADES; SPINOCEREBELLAR ATAXIAS; SUPEROXIDE DISMUTASE; TREATMENT OUTCOME; YOUNG ADULT; ZINC; ZINC SULFATE;

EID: 80555155581     PISSN: 03643190     EISSN: 15736903     Source Type: Journal    
DOI: 10.1007/s11064-011-0496-0     Document Type: Article

References (33)

1. Velázquez-Pérez L, Rodríguez-Labrada R, García-Rodríguez JC et al. (2011) Comprehensive review of spinocerebellar ataxia type 2. Cerebellum doi:10.1007/s12311-011-0265-2
2. Velazquez Perez L, Cruz GS, Santos Falcon N et al (2009) Molecular epidemiology of spinocerebellar ataxias in Cuba: Insights into SCA2 founder effect in Holguin. Neurosci Lett 454(2):157-160
3. Underwood BR, Rubinsztein DC (2008) Spinocerebellar ataxias caused by polyglutamine expansions: A review of therapeutic strategies. Cerebellum 7(2):215-221
4. Gonzalez C, Sánchez G, Quevedo AG et al (2005) Serum and cerebrospinal fluid levels of copper, iron and zinc in patiens with ataxia type SCA-2 from the province of Holguin in Cuba. Therapeutic Basic Dial Clin Neurosci 13(4):12-16
5. World Health Organization Committee (1996) Zinc. In: Trace elements in human nutrition and health. WHO, Geneva, pp 72-104
6. Black MM (2003) The evidence linking zinc deficiency with children's cognitive and motor functioning. J Nutr 133:1473S- 1476S (Pubitemid 36548729)
7. Wall MJ (2005) A role for zinc in cerebellar synaptic transmission? Cerebellum 4:224-229 (Pubitemid 43861182)
8. Fosmire G (1990) Zn toxicity. Am J Clin Nutr 51:225-227
9. Hooper PL, Visconti L, Garry PJ et al (1980) Zinc lowers highdensity lipoprotein-cholesterol levels. J Am Med Assoc 244:1960-1961 (Pubitemid 10014997)
10. Haase H, Overbeck S, Rink L (2008) Zinc supplementation for the treatment or prevention of disease: Current status and future perspectives. Exp Gerontol 48:394-408
11. Schmitz-Hubsch T, du Montcel ST, Baliko L et al (2006) Scale for the assessment and rating of ataxia: Development of a new clinical scale. Neurology 66(11):1717-1720 (Pubitemid 43964628)
12. Esterbaver H, Cheeseman K (1990) Determination of aldehydic lipid peroxidation product: Malondialdehyde and 4-hydroxynonenal. Meth Enzymol 186:407-421 (Pubitemid 20279982)
13. Erdelmeier I, Gerard D, Yadan J et al (1998) Reactions of N methyl-2-phenyl-indole with malondialdehyde and 4-hydroxialkenals. Mechanistic aspects of the colorimetric assay of lipid peroxidation. Chem Res Toxicol 11(10):1184-1194 (Pubitemid 28500799)
14. Mannheim B (1987) Biochemica information. A revised biochemical reference source enzymes for routine, 1st edn. Boehringer Mannheim, Berlin, pp 15-16
15. Shukla G, Hussain T, Chandra S (1987) Possible role of superoxide dismutase activity and lipid peroxide levels in cadmium neurotoxicity: In vivo and in vitro studies in growing rats. Life Sci 14:2215-2225
16. Witko-Sarsat V, Gausson V, Descamps-Latscha B (2003) Are advanced oxidation protein products potential uremic toxins? Kidney Int Suppl 84:S11-S14 (Pubitemid 36513364)
17. Dvergsten CL, Fosmire GJ, Ollerich DA et al (1984) Alterations in the postnatal development of the cerebellar cortex due to zinc deficiency. II. Impaired maturation of Purkinje cells. Brain Res 318:11-20 (Pubitemid 14046363)
18. Dvergsten CL, Johnson LA, Sandstead HH (1984) Alterations in the postnatal development of the cerebellar cortex due to zinc deficiency. III. Impaired dendritic differentiation of basket and stellate cells. Brain Res 318:21-26 (Pubitemid 14046364)
19. Sensi SL, Paoletti P, Bush AI et al (2009) Zinc in the physiology and pathology of the CNS. Nat Rev Neurosci 10:780-791
20. Oteiza PI, Olin KL, Fraga CG et al (1995) Zinc deficiency causes oxidative damage to proteins, lipids and DNA in rat testes. J Nutr 125:823-829
21. Mackenzie GG, Keen CL, Oteiza PI (2002) Zinc status of human IMR-32 neuroblastoma cells influences their susceptibility to iron-induced oxidative stress. Dev Neurosci 24:125-133 (Pubitemid 36151442)
22. Mackenzie GG, Zago MP, Keen CL et al (2002) Low intracellular zinc impairs the translocation of activated NF-kB to the nuclei in human neuroblastoma IMR-32 cells. J Biol Chem 277:34610-34617
23. Bao B, Prasad A, Beck F et al (2010) Zinc decreases C-reactive protein, lipid peroxidation, and inflammatory cytokines in elderly subjects: A potential implication of zinc as an atheroprotective agent. Am J Clin Nutr 91(6):1634-1641
24. Farinati F, Cardin R, D'inca R et al (2003) Zinc treatment prevents lipid peroxidation and increases glutathione availability in Wilson's disease. J Lab Clin Med 141(6):372-377 (Pubitemid 36737149)
25. Marjani A (2005) Plasma lipid peroxidation zinc and erythrocyte Cu-Zn superoxide dismutase enzyme activity in patients with type 2 diabetes mellitus in Gorgan City (South East of the Caspian Sea). Internet J Endocrinol 2(1):1647-1648
26. Velazquez-Perez L, Seifried C, Santos-Falcon N et al (2004) Saccade velocity is controlled by polyglutamine size in spinocerebellar ataxia 2. Ann Neurol 56(3):444-447 (Pubitemid 39166568)
27. Velazquez-Perez L, Seifried C, Abele M et al (2009) Saccade velocity is reduced in presymptomatic spinocerebellar ataxia type 2. Clin Neurophysiol 120(3):632-635
28. Buttner N, Geschwind D, Jen JC et al (1998) Oculomotor phenotypes in autosomal dominant ataxias. Arch Neurol 55(10): 1353-1357 (Pubitemid 28465871)
29. Rodríguez-Labrada R, Velázquez-Pérez L, Seigfried C et al. (2011) Saccadic latency is prolonged in spinocerebellar ataxia type 2 and correlates with the frontal-ecutive dysfunctions. J Neurol Sci doi:10.1016/j.jns.2011.03.033
30. Hutton SB (2008) Cognitive control of saccadic eye movements. Brain Cogn 68(3):327-340
31. Agget P, Harries J (1979) Current status of zinc in health and disease states. Arch Dis Child 54:909-917 (Pubitemid 10174346)
32. Golub M, Takeuchi P, Keen C et al (1996) Activity and attention in zinc-deprived adolescent monkeys. Am J Clin Nutr 64(6):908-915 (Pubitemid 26392878)
33. Arnold LE, DiSilvestro RA (2005) Zinc in attention-deficit/ hyperactivity disorder. J Child Adolesc Psychopharm 15(4): 619-627